Table 4. Development of therapeutic area investigated in clinical trials completed from 2008–2019.
| Therapeutic area | Trials completed 2008–2011 | Trials completed 2012–2015 | Trials completed 2016–2019 | p-value |
|---|---|---|---|---|
| Infections (%) | 401 (12) | 437 (13) | 375 (12) | 0.2669 |
| Circulatory system (%) | 454 (13) | 396 (12) | 410 (13) | 0.1183 |
| Digestive system (%) | 245 (7) | 195 (6) | 148 (5) | 0.0001471 |
| Endocrine/metabolic system (%) | 472 (14) | 468 (14) | 358 (11) | 0.004219 |
| Genitourinary system (%) | 173 (5) | 128 (4) | 127 (4) | 0.02568 |
| Mental disorders (%) | 360 (10.5) | 381 (11) | 220 (7) | 2.15e-06 |
| Musculoskeletal system (%) | 254 (7) | 276 (8) | 207 (6.5) | 0.05394 |
| Neoplasms (%) | 318 (9) | 420 (12) | 480 (15) | 1.03e-12 |
| Nervous system (%) | 308 (9) | 237 (7) | 261 (8) | 0.009974 |
| Respiratory system (%) | 206 (6) | 267 (8) | 213 (7) | 0.008613 |
| Skin (%) | 133 (4) | 161 (5) | 263 (8) | 8.28e-16 |
| Other (%) | 119 (3) | 133 (4) | 98 (3) | 0.2026 |